Alembic Pharma shares gain after drugmaker gets USFDA approval for cancer treatment drug

Alembic Pharma Q4 profit up 29% as US formulations business grows 11%; declares ₹12 dividend

Drug firm Alembic Pharmaceuticals Ltd on Friday (May 15) reported a 29% year-on-year rise in consolidated net profit for the fourth quarter, with profit increasing to ₹202 crore from ₹157 crore a year earlier. Revenue for the quarter rose 4.4% to ₹1,848 crore compared with ₹1,770 crore in the year-ago period. EBITDA declined 16.2% year-on-year…

Read More